Glutamine in Preventing Peripheral Neuropathy in Patients With Multiple Myeloma Receiving Bortezomib - Full Text View

Purpose

This randomized phase II trial studies glutamine in preventing peripheral neuropathy in patients with multiple myeloma who are receiving bortezomib. Glutamine may help prevent peripheral neuropathy in patients receiving chemotherapy

Condition	Intervention	Phase
Chemotherapeutic Agent Toxicity Multiple Myeloma Peripheral Neuropathy	Drug: glutamine Other: quality-of-life assessment Other: placebo	Phase 2


Study Type:	Interventional
Study Design:	Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Investigator) Primary Purpose: Prevention
Official Title:	A Placebo Controlled Study to Estimate the Effect Size of Glutamine as a Supplement to Prevent Bortezomib-induced Peripheral Neuropathy in Multiple Myeloma Patients

Resource links provided by NLM:

MedlinePlus related topics: Multiple Myeloma Peripheral Nerve Disorders

Drug Information available for: Glutamine

Genetic and Rare Diseases Information Center resources: Multiple Myeloma

U.S. FDA Resources

Further study details as provided by Case Comprehensive Cancer Center:

Primary Outcome Measures:

Degree of Peripheral Neuropathy (PNP) [ Time Frame: at 4 months (after 4 courses) ] [ Designated as safety issue: No ]
The Neuropathy Impairment Score -Lower Limbs (NIS-LL) is the objective measurement of PNP symptoms. The degree of PNP will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) v4.03. The CTCAE is a 0-5 scale that assesses severity of neuropathy related to cancer therapy with higher scores meaning more symptoms A difference of 2 points between groups is considered significant. This measure will be performed at baseline and at 4 months.

Secondary Outcome Measures:

Adherence to bortezomib treatment [ Time Frame: At the end of every month (course) for 4 months ] [ Designated as safety issue: No ]
Adherence to bortezomib treatment will be assessed by comparing cumulative body surface area adjusted doses administered during the first 4 cycles between placebo and glutamine groups.
RR (complete remission [sCR+CR+very good partial remission [VGPR]+partial remission [PR]) [ Time Frame: At the beginning of each month and at the end of month 4 ] [ Designated as safety issue: No ]
RR (sCR+CR+VGPR+PR) according to uniform international response criteria and CBR (RR+MR according to modified EBMT criteria) will be assessed with SPEP, 24h UPEP, serum urine immunofixation, and serum free light chain assay at the start of each cycle and after completion of the 4th cycle.
Quality of life [ Time Frame: At baseline and at the end of month 4 ] [ Designated as safety issue: No ]
Quality of life will be measured on the 27-item Functional Assessment of Cancer Therapy-General (FACT-G) plus the 11-item neurotoxicity sub-scale (FACT/GOG-Ntx) at the start of each cycle and after completion of the 4th cycle. Higher scores represent better quality of life.


Enrollment:	9
Study Start Date:	February 2013
Study Completion Date:	November 2013
Primary Completion Date:	November 2013 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
Experimental: Arm I (preventative nutritional supplementation) Patients receive glutamine PO BID. Courses repeat every 28 days for 4 months in the absence of disease progression or unacceptable toxicity.	Drug: glutamine Dose of 15 grams twice times daily (to equal 30 grams a day) for a period of 4 months. Other Names: 2-aminoglutaramic acid Gln glutamic acid 5-amide L-glutamine NutreStore Other: quality-of-life assessment Ancillary studies Other Name: quality of life assessment
Placebo Comparator: Arm II (placebo) Patients receive placebo PO BID. Courses repeat every 28 days for 4 months in the absence of disease progression or unacceptable toxicity.	Other: quality-of-life assessment Ancillary studies Other Name: quality of life assessment Other: placebo Given PO Other Name: PLCB

Detailed Description:

PRIMARY OBJECTIVES:

I. Estimate the objective effect size of glutamine compared to placebo as a prophylactic intervention to prevent bortezomib-induced peripheral neuropathy in multiple myeloma patients 4 months after their first dose of study drug.

SECONDARY OBJECTIVES:

I. Estimate whether glutamine delays or prevents the onset or worsening of any neuropathy as determined by National Cancer Institute (NCI)-Common Terminology Criteria for Adverse Events (CTCAE) v4.03 criteria.

II. Determine if glutamine may improve adherence to bortezomib therapy.

III. Assess response rate (RR) and clinical benefit response rate (CBR) according to uniform international response criteria and modified European Group for Blood and Marrow Transplantation (EBMT) criteria.

IV. Determine if glutamine may improve quality of life (QOL) at 4 months.

OUTLINE: Patients are randomized to 1 of 2 treatment arms.

ARM I: Patients receive glutamine orally (PO) twice daily (BID). Courses repeat every 28 days for 4 months in the absence of disease progression or unacceptable toxicity.

ARM II: Patients receive placebo PO BID. Courses repeat every 28 days for 4 months in the absence of disease progression or unacceptable toxicity.

Eligibility


Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Patients with a diagnosis of multiple myeloma who received bortezomib at a dose of 1.3mg/m2 SQ weekly
No evidence of severe pre-existing peripheral neuropathy, NCI-CTCAE v4.03 =< 2
Performance status =< 2 on the Eastern Cooperative Oncology Group (ECOG) performance scale

Exclusion Criteria:

Concurrent use of thalidomide, vincristine, platinum compound, or other agent known to cause significant neuropathy (concurrent lenalidomide will be allowed)
Hospitalization with clinical evidence of active infections as manifested by recurrent fevers, positive blood culture results, or requiring intravenous antibiotic therapy
Inadequate liver and renal function with liver transaminases 3x the upper limit of normal
Glomerular filtration rate (GFR) according to Cockcroft-Gault < 30 mL/min
Uncontrolled congestive heart failure
Uncontrolled mood disorders
Fasting blood glucose >150mg/dL or blood sugar (non-fasting) >200mg/dL if no history of diabetes. Uncontrolled diabetes with HgA1C greater 7% with last evaluation.
Seizure disorder
Monosodium glutamate (MSG) allergy or soy allergy
Life expectancy of shorter than 3 months based on clinical laboratory parameters and the investigator's opinion
Uncorrected Vitamin B12 or folate deficiency on last evaluation.
Use of over the counter (OTC) supplements other than one multivitamin tablet a day
Women who are pregnant or breastfeeding

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01783522

Locations


United States, Ohio
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center
Cleveland, Ohio, United States, 44195

Sponsors and Collaborators

Beth Faiman

National Cancer Institute (NCI)

Investigators


Principal Investigator:	Beth Faiman	Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center

More Information

No publications provided


Responsible Party:	Beth Faiman, Principal Investigator, Case Comprehensive Cancer Center
ClinicalTrials.gov Identifier:	NCT01783522 History of Changes
Other Study ID Numbers:	CASE2A10, NCI-2011-01866
Study First Received:	January 31, 2013
Last Updated:	December 10, 2013
Health Authority:	United States: Food and Drug Administration

Additional relevant MeSH terms:


Peripheral Nervous System Diseases Multiple Myeloma Neoplasms, Plasma Cell Blood Protein Disorders Cardiovascular Diseases Hematologic Diseases Hemorrhagic Disorders Hemostatic Disorders Immune System Diseases	Immunoproliferative Disorders Lymphoproliferative Disorders Neoplasms Neoplasms by Histologic Type Nervous System Diseases Neuromuscular Diseases Paraproteinemias Vascular Diseases

ClinicalTrials.gov processed this record on February 25, 2015